An Expanded Access Program of Onvansertib in Combination with FOLFIRI and Bevacizumab for the Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Phone: (800) 411-7999
An Expanded Access Program of Onvansertib in Combination with FOLFIRI and Bevacizumab for the Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)